Drug intelligence / Profile preview

sTim-3-Ig

Development stage: Preclinical
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

sTim-3-Ig is a soluble fusion protein designed to block the T cell immunoglobulin and mucin domain protein 3 (Tim-3) pathway. Tim-3 is a negative immune regulator involved in the pathophysiology of sepsis. By blocking Tim-3 signaling, sTim-3-Ig aims to modulate immune responses, potentially exacerbating proinflammatory macrophage responses and lymphocyte apoptosis in early sepsis, and enhancing anti-inflammatory shifts in later stages, thereby influencing T helper cell and macrophage activity. This mechanism suggests a role in regulating immune deviation and immunosuppression in conditions like sepsis.

Targets

HMGB1 (High mobility group protein B1)CEACAM1LGALS9 (Galectin-9)

Beyond the preview

Go deeper on sTim-3-Ig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sTim-3-Ig.

Explore the full profile